Appropriate questionnaires for knee arthroplasty

  • M. J. Dunbar
    Dalhousie University, Suite 4822, QE II Health Sciences Centre, 1796 Summer Street, Halifax, Nova Scotia, Canada B3H 3A7.
  • O. Robertsson
    Department of Orthopaedics, Lund University Hospital, S-221 85 Lund, Sweden.
  • L. Ryd
    Department of Orthopaedics, Lund University Hospital, S-221 85 Lund, Sweden.
  • L. Lidgren
    Department of Orthopaedics, Lund University Hospital, S-221 85 Lund, Sweden.

書誌事項

タイトル別名
  • RESULTS OF A SURVEY OF 3600 PATIENTS FROM THE SWEDISH KNEE ARTHROPLASTY REGISTRY
公開日
2001-04
権利情報
  • https://online.boneandjoint.org.uk/TDM
DOI
  • 10.1302/0301-620x.83b3.0830339
公開者
British Editorial Society of Bone & Joint Surgery

この論文をさがす

説明

<jats:p> The Swedish Knee Arthroplasty Registry (SKAR) has recorded knee arthroplasties prospectively in Sweden since 1975. The only outcome measure available to date has been revision status. While questionnaires on health outcome may function as more comprehensive endpoints, it is unclear which are the most appropriate. We tested various outcome questionnaires in order to determine which is the best for patients who have had knee arthroplasty as applied in a cross-sectional, discriminative, postal survey. </jats:p><jats:p> Four general health questionnaires (NHP, SF-12, SF-36 and SIP) and three disease/site-specific questionnaires (Lequesne, Oxford-12, and WOMAC) were tested on 3600 patients randomly selected from the SKAR. Differences were found between questionnaires in response rate, time required for completion, the need for assistance, the efficiency of completion, the validity of the content and the reliability. The mean overall ranks for each questionnaire were generated. The SF-12 ranked the best for the general health, and the Oxford-12 for the disease/site-specific questionnaires. These two questionnaires could therefore be recommended as the most appropriate for use with a large knee arthroplasty database in a cross-sectional population. </jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ